Compugen to Present Cancer Immunotherapy Targets at Two Tumor Immunology Conferences This Month
February 02 2015 - 6:39AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced that it will
present aspects of its immune checkpoint related research at two
scientific conferences this month.
On February 9, Arthur Machlenkin, PhD, Head of Immunology Group
at Compugen, will deliver an oral presentation at the Keystone
Symposia: Tumor Immunology - Multidisciplinary Science Driving
Combination Therapy being held from February 8-13, in Banff,
Canada. In his talk titled Identification of Novel
Immuno-Modulatory Targets for Cancer Immunotherapy, Dr. Machlenkin
will discuss Compugen’s discovery approach in identifying 11 novel
immune checkpoint candidates for cancer immunotherapy. In addition,
Dr. Machlenkin will present experimental data demonstrating the
immunomodulatory function and expression patterns of two
Compugen-discovered immune checkpoints: CGEN-15049 and
CGEN-15027.
On February 16, Ofer Levy, PhD, Principal Scientist at Compugen,
will deliver a presentation titled Computational Discovery and
Experimental Validation of Novel Players in the Immuno-Oncology
Arena at the Onco-Immunology Meeting: Prospects of Immunity for
Precision Cancer Medicine, to be held at the Israel Institute of
Advanced Studies, in Jerusalem, Israel. In his talk Dr. Levy will
give an overview on the design and implementation of immune assays
aimed at exploring the potential role of Compugen’s novel targets
as immune checkpoint candidates.
About Compugen
Compugen is a leading drug discovery company focused on
monoclonal antibodies and therapeutic proteins to address important
unmet needs in the fields of oncology and immunology. The
Company utilizes a broad and continuously growing integrated
infrastructure of proprietary scientific understandings and
predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in
silico (by computer) prediction and selection of novel drug
target candidates, which are then advanced in its Pipeline Program.
The discovery and development of monoclonal antibody therapeutic
candidates against selected Compugen-discovered novel target
candidates is performed by Compugen’s wholly-owned U.S. subsidiary
located in South San Francisco. The Company's business model
includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. For additional information, please visit
Compugen's corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as “will,” “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these and other
factors are discussed in the "Risk Factors" section of Compugen’s
most recent Annual Report on Form 20-F as filed with the Securities
and Exchange Commission as well as other documents that may be
subsequently filed by Compugen from time to time with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@cgen.com
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024